KBC Group’s Cogent Biosciences COGT Stock Holding History

KBC Group’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$153K	Buy	3,946 +1,272	+48%	+$44.5K	﹤0.01%	1162
2026 Q1	$103K	Buy	+2,674	New	+$98.7K	﹤0.01%	1301

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

KBC Group's COGT Position: Q2 2026 in Review

KBC Group increased its Cogent Biosciences (COGT) stake by 48% in Q2 2026, buying an estimated $44.5K and bringing the position to 3,946 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1162.

KBC Group first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

KBC Group held 3,946 shares of Cogent Biosciences worth $153K as of Q2 2026.
KBC Group bought 1,272 Cogent Biosciences shares in Q2 2026, an estimated $44.5K.
Cogent Biosciences made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1162 holding.
KBC Group first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.